Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes

Sarah A Hitchen, Nick S R Lan, James M Rankin, Robert Larbalestier, Bu B Yeap, P Gerry Fegan

Research output: Contribution to journalArticlepeer-review

Abstract

In this real-world study, the main barriers for not initiating SGLT2 inhibitor therapy early after an acute cardiac event are prescribing criteria around glycated haemoglobin and renal function. Initiation of SGLT2 inhibitors near to, or at, hospital discharge following the cardiac event was not associated with 30-day diabetic ketoacidosis readmissions.

Original languageEnglish
Article number108057
JournalJournal of Diabetes and Its Complications
DOIs
Publication statusE-pub ahead of print - 29 Sep 2021

Fingerprint

Dive into the research topics of 'Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes'. Together they form a unique fingerprint.

Cite this